Nektar (NKTR) Therapeutics announced the company has completed target enrollment in its REZOLVE-AA Phase 2b study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes
- NKTR Earnings this Week: How Will it Perform?
- Nektar announces clinical trial agreement to evaluate Rezpegaldesleukin
- Nektar management to meet virtually with BTIG
- Biotech Alert: Searches spiking for these stocks today